NCT03647163 2025-09-16Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid TumorsVyriad, Inc.Phase 1/2 Active not recruiting33 enrolled